NATCO Pharma Management
Management criteria checks 1/4
NATCO Pharma's CEO is Rajeev Nannapaneni, appointed in Jun 2012, has a tenure of 12.5 years. directly owns 0.63% of the company’s shares, worth ₹1.60B. The average tenure of the management team and the board of directors is 7.8 years and 1.5 years respectively.
Key information
Rajeev Nannapaneni
Chief executive officer
₹98.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.5yrs |
| CEO ownership | 0.6% |
| Management average tenure | 7.8yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
CEO
Rajeev Nannapaneni (47 yo)
12.5yrs
Tenure
₹98,670,000
Compensation
Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Chairman | 43.3yrs | ₹100.77m | 25.1% ₹ 63.7b | |
| CEO & Vice Chairman | 12.5yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| Chief Financial Officer | 8.8yrs | ₹13.36m | no data | |
| President of Technical Affairs & Whole Time Director | no data | ₹33.69m | 0.030% ₹ 76.7m | |
| Company Secretary & Compliance Officer | 2.7yrs | ₹2.61m | no data | |
| Executive VP of Corporate Engineering Services & Whole Time Director | no data | ₹20.16m | 0.023% ₹ 58.3m | |
| Executive VP of Technical Operations & Director | 7.8yrs | ₹32.12m | 0.013% ₹ 33.0m | |
| VP & Head of Operations | no data | no data | no data | |
| Executive Vice President of Corporate Affairs | no data | no data | no data | |
| Vice President of Marketing & Sales - Domestic | less than a year | no data | no data | |
| Senior Vice President of HR & Organisational Development | no data | no data | 0.0062% ₹ 15.7m | |
| Executive Vice President of R&D | 30.7yrs | no data | 0.025% ₹ 62.5m |
7.8yrs
Average Tenure
65yo
Average Age
Experienced Management: 524816's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Chairman | 43.3yrs | ₹100.77m | 25.1% ₹ 63.7b | |
| CEO & Vice Chairman | 19.1yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| President of Technical Affairs & Whole Time Director | 9.8yrs | ₹33.69m | 0.030% ₹ 76.7m | |
| Executive VP of Corporate Engineering Services & Whole Time Director | 10.1yrs | ₹20.16m | 0.023% ₹ 58.3m | |
| Executive VP of Technical Operations & Director | 2.3yrs | ₹32.12m | 0.013% ₹ 33.0m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
1.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: 524816's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NATCO Pharma Limited is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |